ClinicalTrials.gg
CompletedNCT07790120Updated Aug 27, 2026

A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A Phase 3 interventional study of SAL0120 and Placebo in Uncontrolled Hypertension and Resistant Hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Oct 2024, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.

Enrollment
152nd of 306
256 · median 255
Started
2024
with 29 others
Phase 3
44 of 408
6 open now
Registered
395th of 408
by date
Lead sponsor
9 of 408
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 408 studies in Hypertension with a site in China, this one is the 152nd largest by enrollment of the 306 interventional ones that give a count, is one of 30 that started in 2024, is one of 44 in phase 3, and was the 395th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 910 are open to participants now.

Browse Hypertension studies →

Open to participants now

123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 408 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

This is a Phase II, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, and effect of low, middle and high dose of SAL0120 versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 256 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

03

Conditions studied

  • Uncontrolled Hypertension
  • Resistant Hypertension

Browse trials for

Keywords

  • Uncontrolled Hypertension
  • Resistant Hypertension
  • SAL0120
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years (inclusive), male or female
  • Diagnosis of essential hypertension
  • Mean seated systolic blood pressure (msSBP) ≥ 140 mmHg and \< 180 mmHg at screening
  • At screening, subjects must meet one of the following criteria (A or B):

A: Uncontrolled hypertension (uHTN)

  • Receiving a stable regimen of the following antihypertensive drugs at the maximum tolerated dose for at least 4 weeks prior to screening (as combination therapy or single-pill combination), as judged by the investigator, and in whom an additional antihypertensive agent is considered at screening:

ACEI/ARB/ARNI + diuretic CCB + diuretic Beta-blockers used for the treatment of other conditions (e.g., migraine, heart failure, coronary artery disease) are not considered antihypertensive agents.

B: Resistant hypertension (rHTN):

  • Receiving a stable regimen of the following antihypertensive drugs at the maximum tolerated dose for at least 4 weeks prior to screening (as combination therapy or single-pill combination), as judged by the investigator, and in whom an additional antihypertensive agent is considered at screening:

ACEI/ARB/ARNI + CCB + diuretic ACEI/ARB/ARNI + CCB + diuretic + beta-blocker/aldosterone receptor antagonist/centrally acting agent/alpha-blocker Beta-blockers used for the treatment of other conditions (e.g., migraine, heart failure, coronary artery disease) are not considered antihypertensive agents.

  • msSBP ≥ 140 mmHg and \< 180 mmHg at the end of the single-blind run-in period or prior to randomization
  • All male subjects and female subjects of agree to use highly effective methods from the date of signing the ICF until 1 month after discontinuation of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension (msSBP ≥ 180 mmHg and/or msDBP ≥ 110 mmHg); malignant hypertension, hypertensive emergency, hypertensive crisis, or hypertensive encephalopathy;
  • History or diagnostic evidence of secondary hypertension, including but not limited to: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary aldosteronism, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension;
  • Medication compliance \< 80% or > 120% during the single-blind run-in period;
  • laboratory abnormalities, including but not limited to: serum and/or AST > 2.5 × (ULN); total > 2 × ULN; \< 30 mL/min/1.73 m² estimated by the simplified Modification of Diet in Renal Disease (MDRD) equation; any clinically significant laboratory abnormality that, in the investigator's opinion, may interfere with the evaluation of efficacy and/or safety data of this study; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus ( > 8.0%);
  • Severe obesity with (BMI) > 40 kg/m² (BMI = weight (kg) / height² (m²));
  • \< 100 g/L, or blood transfusion for anemia within 3 months prior to screening;
  • Subjects with a documented history of anxiety or depression;
  • Female subjects who are pregnant, breastfeeding, or have a positive pregnancy test
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    SAL0120 low dose

    SAL0120:Administered orally, once daily (QD)

    Drug: SAL0120

  • Placebo comparator
    Placebo

    Placebo:Administered orally, once daily (QD)

    Drug: Placebo

  • Experimental
    SAL0120 Middle dose

    SAL0120: Administered orally, once daily (QD)

    Drug: SAL0120

  • Experimental
    SAL0120 high dose

    SAL0120: Administered orally, once daily (QD)

    Drug: SAL0120

Interventions

  • DrugSAL0120

    SAL0120 Administered orally, once daily (QD): Low dose, Middle dose, High dose

  • DrugPlacebo

    Placebo Administered orally, once daily (QD)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Seated Systolic Blood Pressure for low, middle and high dose of SAL0120

    To assess the effect of low, middle and high dose of SAL0120 versus placebo on seated systolic blood pressure at Week 12

    Time frame: at Week 12

  2. Change From Baseline in Seated Systolic Blood Pressure for low, middle and high dose of SAL0120

    To assess the effect of low, middle and high dose of SAL0120 versus placebo on seated systolic blood pressure at Week 4, 8

    Time frame: At Week 4, 8

07

Study locations

1 site
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jul 2026, 20 months.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 20 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 27, 2026
StartActual
Oct 29, 2024
Primary completionActual
Jul 2, 2026
CompletionActual
Jul 2, 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07790120
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Oct 29, 2024
Primary completion
Jul 2, 2026
Completion
Jul 2, 2026
Last update
Aug 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion